TABLE 1

Participant demographics

Subjects	25^#
Age years	54 (23–81)
Female/male	68/32
Smoking status current/past/none	0/64/36
Living alone or with children/with partner or other adult	20/80
Living in a socially disadvantaged area^¶	48
Living in a regional location, outside a major city⁺	16
Age asthma diagnosed years	17 (1–50)
Daily prescribed inhaled corticosteroid dose µg^§	1600 (1200, 2400)
Also prescribed omalizumab	32
Asthma Control Test score^ƒ	16 (12, 19)
One or more hospital admissions in last 12 months	36

Data are presented as n, median (range), % or median (upper, lower quartile). ^#: living in state: New South Wales/Australian Capital Territory 44%, Victoria 20%, Queensland 12%, South Australia 8%, Western Australia 8%, Tasmania 8% (32% AustralAsian Severe Asthma Network-referred); ^¶: socioeconomic indices for area quintile ≤3 [26]; ⁺: only 10% of Australians live outside major cities [27]; ^§: beclomethasone dipropionate equivalent; ^ƒ: Asthma Control Test scores reflect asthma symptom control over the previous 4 weeks, classified as: 5–15=very poorly controlled, 16–19=not well controlled and 20–25=well controlled [14] (the range of scores in this sample was 7–23; all participants satisfied the European Respiratory Society/American Thoracic Society Task Force criteria for severe refractory asthma [1]).